Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of TNM002 in Healthy Chinese Adults
NCT05842798Phase 1Completed
- Sponsor
- Trinomab Pharmaceutical
- Start
- Oct 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of Atorva in Tetanus (3 arms), sponsored by Trinomab Pharmaceutical. Primary endpoints: Adverse Events (AEs), Number of participants with clinically significant abnormality in physical examinations and 6 more. Started Oct 2021; status: completed.
02
Drugs
Atorva
03
Conditions
Tetanus
Beyond the preview
Go deeper on NCT05842798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05842798.